MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Stool DNA testing for colorectal cancer

Back to colon cancer blog Blogs list Cancer blog  


Subscribe To Colon Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Stool DNA testing for colorectal cancer




The first generation of a stool DNA test to identify early colorectal cancer has limitations, as per a Mayo Clinic-led study reported in the Oct. 7, 2008, issue of Annals of Internal Medicine Results did not corroborate findings of an earlier multicenter study that showed stool DNA testing was more accurate than fecal blood testing for colorectal cancer detection. *.

"But the concerns we identified with stool DNA testing are all solvable," says David Ahlquist, M.D., lead researcher in the study that included 4,482 participants and 22 academic medical centers. Scientists have hoped that stool DNA testing could be the user-friendly and accurate screening tool that would increase screening numbers.



Stool DNA testing for colorectal cancer

More than half of adults in the United States have never been screened for colorectal cancer, the second-leading cause of cancer deaths. While available screening tools work, the most effective tests involve time, effort and costs. For example, colonoscopy requires fasting, bowel cleansing, a doctor visit, sedation, an invasive procedure and lost work time -- factors that contribute to low screening participation.

This blinded study, conducted from 2001 to 2007, compared screening effectiveness of two widely used fecal blood tests (Hemoccult and HemoccultSensa) with a stool DNA test in average-risk patients, ages 50 to 80. The DNA test used was the prototype for PreGenPlus, the first commercially-used stool DNA test, and waccording toformed on samples sent to EXACT Sciences in Marlborough, Mass. All participants underwent a colonoscopy, the gold standard in current screening. Scientists used colonoscopy as the benchmark to detect cancer or premalignant polyps.

In the fecal blood screening, lab technicians searched for unseen traces of blood from stool that patients smeared onto a card. The presence of blood might indicate colorectal cancer. However, tumors bleed.

intermittently, which limits the test's accuracy for cancer detection. Three stool samples were tested for blood for each participant, the typical approach for fecal blood screening.

In DNA testing, scientists used sensitive laboratory tools to identify DNA from cells shed from cancer and premalignant polyps in stool samples. Only one sample was mandatory because DNA shedding is thought to becontinuous.

At about the study's halfway point, when 2,497 patients had been tested, scientists compiled an interim analysis. "All stool tests performed suboptimally," says Dr. Ahlquist. "The stool DNA test detected 20 percent of cancer and premalignant polyps, in comparison to 11 percent by Hemoccult and 20 percent by HemoccultSensa."

"We didn't believe that stool DNA test performance was good enough to justify continuing without some changes," he says. Dr. Ahlquist and his colleagues switched to a second-generation DNA test with improvements including a better method to capture DNA from stool and a more accurate panel of DNA markers.

With those changes, the stool DNA test performed significantly better than either of the fecal blood tests. "The new DNA test detected half of all the cancers and large polyps," says Dr. Ahlquist. In comparison, Hemoccult detected only one-sixth of cancers and large polyps, and HemoccultSensa found one-fourth of cancers and large polyps.

Importantly, the second-generation DNA test detected 46 percent of the premalignant polyps, in comparison to 10 percent detected by Hemoccult and 17 percent by HemoccultSensa. "If the precancerous polyps are not detected, cancer cannot be prevented. So, this result was most encouraging," says Dr. Ahlquist.

Dr. Ahlquist noted that the study, funded by the National Cancer Institute, honed in on weaknesses in the stool DNA screening that can be fixed to make it a more practical, accurate screening tool.

Sample degradation: Study participants were provided kits to collect and mail stool samples. When the samples arrived at Mayo Clinic's laboratory two to three days after collection, much of the DNA in samples had degraded and was not usable. "We have learned that adding a preservative at the time of collection eliminates DNA breakdown and can boost tumor detection rates further," says Dr. Ahlquist. That step will be important in future patient screening, should the test become widely available.

DNA markers: Markers used in the first-generation DNA test missed a number of polyps and cancers evident in the low detection rate in the interim results. "The second-generation screen, with a broader assay, improved results," says Dr. Ahlquist. "We will be able to select even more accurate marker combinations for future tests."

DNA detection: Detecting the minute amounts of tumor DNA in stool is very challenging. Tumor DNA may account for less than one-millionth of total stool DNA. The instruments used to measure DNA for the interim results could not always detect the DNA. Since then, Mayo Clinic and others have improved the sensitivity of the measurement tools using digital polymerase chain reaction (PCR), a technique to duplicate DNA, and other analytical techniques.

"To prevent colorectal cancer deaths, we need an easy-to-use screening tool that consistently finds premalignant polyps," says Dr. Ahlquist. "Stool DNA testing is evolving quickly and may soon fill that need."

Earlier this year, the American Cancer Society endorsed stool DNA testing to detect colorectal cancer. Dr. Ahlquist advises that current hurdles to its use are that it is not widely available, has not been approved by the U.S. Food and Drug Administration, and is not covered by most insurers.


Posted by: Sue    Source




Did you know?
The first generation of a stool DNA test to identify early colorectal cancer has limitations, as per a Mayo Clinic-led study reported in the Oct. 7, 2008, issue of Annals of Internal Medicine Results did not corroborate findings of an earlier multicenter study that showed stool DNA testing was more accurate than fecal blood testing for colorectal cancer detection. *.

Medicineworld.org: Stool DNA testing for colorectal cancer

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.